benzinga.comWitnessing An Insider Decision, Gary Charles Robb Exercises Options Valued At $328K At Corcept Therapeutics4 days ago
benzinga.comInsider Decision: Gary Charles Robb Offloads $225K Worth Of Corcept Therapeutics Stock2 months ago
benzinga.comMajor Update: LEONARD BAKER JR At Corcept Therapeutics Exercises Options, Realizing $03 months ago
businesswire.comCorcept Therapeutics to Announce Fourth Quarter and Full-Year 2024 Financial Results, Provide Corporate Update and Host Conference Call7 months ago
businesswire.comCorcept Submits New Drug Application for Relacorilant as a Treatment for Patients With Hypercortisolism8 months ago
businesswire.comCorcept Announces Positive Results in Treatment Phase of CATALYST Trial in Patients With Hypercortisolism (Cushing’s Syndrome) and Difficult-to-Control Diabetes9 months ago
businesswire.comCorcept Announces Positive Results in Treatment Phase of CATALYST Trial in Patients With Hypercortisolism (Cushing’s Syndrome) and Difficult-to-Control Diabetes9 months ago
CashuCorcept Therapeutics' Leadership Moves Signal Confidence in Future Growth and Strategic Direction3 days ago
CashuCorcept Therapeutics: Executive Confidence and Commitment to Growth Through Stock Options Exercise5 days ago
CashuCorcept Therapeutics: Leading Innovations in CNS Disorder Treatments and Patient Advocacy28 days ago